Summary of treatment results of recent clinical trials for children and adolescents with relapsed/refractory T-cell lymphoblastic lymphoma
| Trial . | Study y . | Study population . | Number of patients with r/r/ T-LL (total number of r/r patients) . | Treatment . | Outcome . | Outcome w/ HSCT . |
|---|---|---|---|---|---|---|
| CCG-591269 | 1991-1994 | r/r HD/NHL | 68 NHL (97) | DECAL ± HSCT | 23% ± 5% EFS; 31% ± 14% OS (all NHL, not just T-LL) | No significant benefit to HSCT |
| BFM 90 and 9558 | 1990-2003 | T/B-LLy | 28 (251) | ALL-BFM ± HSCT | 14% ± 7% OS | 42% OS |
| JPLSG13 | 1996-2004 | T/B-LLy | 32 (48) | ALL-backbone ± HSCT | 32.8% ± 8.6% OS | HR 2.64 for absence of HSCT |
| CIBMTR70 | 1990-2005 | NHL | 53 LL (182) | Allo/Auto HSCT | 40% EFS (allo); 4% EFS (auto) | |
| AIEOP-NHL-9771 | 1997-2007 | T/B-LLy | 21 | LSA2-L2 ± HSCT | OS 28% | 41% OS (5/6 allo) |
| EORTC 58951 and LMT 9672 | 1997-2008 | T/B-LLy | 18 (23) | Various chemo regimens ± HSCT | 8.7% EFS; 8.7% OS | 20% OS |
| AALL07P159 | 2009-2014 | r/r T/B-ALL, LLy | 10 (135) | Bortezomib + 4-drug re-induction | 70% ORR | NA |
| MD Anderson venetoclax study65 | T/B-ALL, LLy | 6 (18) | Venetoclax + chemo | ORR 83%, PFS 7.34 mo, OS 9.14 mo | NA | |
| Delphinus (NCT03384654)62 | 2018-2022 | r/r T-ALL, LLy | 10 | BFM + daratumumab | 40% CR | NA |
| Case study64 | r/r T-ALL, LLy | 1 (2) | Daratumumab + nelarabine | Alive at 3.5 years s/p allo-HSCT | NA | |
| Campus ALL study73 | 2018-2020 | r/r T/B-ALL, LLy | 1 (20) | Daratumumab ± chemo | Non-responder | NA |
| CD7 CAR T cell therapy68 | 2020-2021 | r/r T-ALL, LLy | 6 | NS7CAR T therapy | 100% CRi on day 28 | NA |
| Phase 1 study of venetoclax + navitoclax + chemotherapy (NCT03181126) | 2017-2019 | r/r T-ALL, LLy | 2 (47) | Venetoclax + low-dose navitoclax + chemo | 60% CR | NA |
| Trial . | Study y . | Study population . | Number of patients with r/r/ T-LL (total number of r/r patients) . | Treatment . | Outcome . | Outcome w/ HSCT . |
|---|---|---|---|---|---|---|
| CCG-591269 | 1991-1994 | r/r HD/NHL | 68 NHL (97) | DECAL ± HSCT | 23% ± 5% EFS; 31% ± 14% OS (all NHL, not just T-LL) | No significant benefit to HSCT |
| BFM 90 and 9558 | 1990-2003 | T/B-LLy | 28 (251) | ALL-BFM ± HSCT | 14% ± 7% OS | 42% OS |
| JPLSG13 | 1996-2004 | T/B-LLy | 32 (48) | ALL-backbone ± HSCT | 32.8% ± 8.6% OS | HR 2.64 for absence of HSCT |
| CIBMTR70 | 1990-2005 | NHL | 53 LL (182) | Allo/Auto HSCT | 40% EFS (allo); 4% EFS (auto) | |
| AIEOP-NHL-9771 | 1997-2007 | T/B-LLy | 21 | LSA2-L2 ± HSCT | OS 28% | 41% OS (5/6 allo) |
| EORTC 58951 and LMT 9672 | 1997-2008 | T/B-LLy | 18 (23) | Various chemo regimens ± HSCT | 8.7% EFS; 8.7% OS | 20% OS |
| AALL07P159 | 2009-2014 | r/r T/B-ALL, LLy | 10 (135) | Bortezomib + 4-drug re-induction | 70% ORR | NA |
| MD Anderson venetoclax study65 | T/B-ALL, LLy | 6 (18) | Venetoclax + chemo | ORR 83%, PFS 7.34 mo, OS 9.14 mo | NA | |
| Delphinus (NCT03384654)62 | 2018-2022 | r/r T-ALL, LLy | 10 | BFM + daratumumab | 40% CR | NA |
| Case study64 | r/r T-ALL, LLy | 1 (2) | Daratumumab + nelarabine | Alive at 3.5 years s/p allo-HSCT | NA | |
| Campus ALL study73 | 2018-2020 | r/r T/B-ALL, LLy | 1 (20) | Daratumumab ± chemo | Non-responder | NA |
| CD7 CAR T cell therapy68 | 2020-2021 | r/r T-ALL, LLy | 6 | NS7CAR T therapy | 100% CRi on day 28 | NA |
| Phase 1 study of venetoclax + navitoclax + chemotherapy (NCT03181126) | 2017-2019 | r/r T-ALL, LLy | 2 (47) | Venetoclax + low-dose navitoclax + chemo | 60% CR | NA |